

# MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053

## AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2011

Rs.in Lacs

Sr. No.	PARTICULARS	For the year ended on	
		31.03.2011 (AUDITED)	31.03.2010 (AUDITED)
1	Income		
	a>. Net Sales/ Income from Operations	15,543.76	19,956.21
	b>. Other Operating Income	168.64	160.37
	<b>Total Income</b>	<b>15,712.40</b>	<b>20,116.58</b>
2	Expenditure		
	a>. (Increase)/Decrease in stock in trade	3.55	1,198.19
	b>. Consumption of Material & Purchases	10,728.29	13,443.92
	c>. Employee Cost	1,137.68	1,069.13
	d>. Depreciation	1,464.39	983.92
	e>. Other Expenditure	5,074.43	1,880.92
	<b>Total Expenditure</b>	<b>18,408.34</b>	<b>18,576.08</b>
3	Profit from Operations before other income		
	Interest & Exceptional Items (1-2)	(2,695.94)	1,540.50
4	Other Income	-	-
5	Profit before Interest & Exceptional item (3+4)	(2,695.94)	1,540.50
6	Interest	10,576.67	1,477.83
7	Profit after Interest but before Tax & Exceptional items	(13,272.61)	62.67
8	Exceptional items	-	-
9	<b>Profit/(Loss) from Ordinary activities before Tax (7+8)</b>	<b>(13,272.61)</b>	<b>62.67</b>
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	484.63	33.69
11	<b>Net Profit/(Loss) from Ordinary activities after tax(9-10)</b>	<b>(13,757.24)</b>	<b>28.98</b>
12	Less: Extraordinary Item-(Loss)/Profit on sale of API division/Fixed assets	(8,021.68)	-
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>(21,778.92)</b>	<b>28.98</b>
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.07	3,678.05
15	Reserve Excluding Revaluation Reserve as per Balance sheet of Previous Accounting year	6,031.23	12,536.52
16	a>. Earnings Per Share (Basic & Diluted) (before extraordinary items.Rs.)	(3.74)	0.01
	b>. Earnings Per Share( Basic & Diluted) (after Extraordinary items- Rs.)	(5.92)	0.01
17	Aggregate of Public Shareholding:		
	- Number of Shares	189,823,694	189,822,361
	- Percentage of Holding	51.61%	51.61%
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510
	a>. Pledged/Encumbered		
	- Number of Shares	NIL	NIL
	- Percentage of Holding	N.A	N.A
	(as a % of the total shareholding of Promoter and Promoter Group)		
	- Percentage of Holding	N.A	N.A
	(as a % of the total share capital of the Company)		
	a>. Non-encumbered		
	- Number of Shares	177,983,510	177,983,510
	- Percentage of Holding	100%	100%
	(as a % of the total shareholding of Promoter and Promoter Group)		
	- Percentage of Holding	48.39%	48.39%
	(as a % of the total share capital of the Company)		




**Notes:**



- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28.05.2011.
- 2 The company has on 28th July ,2010 entered into a Business Transfer Agreement with Kores(India) Limited and accordingly sold and transferred its Active Pharmaceutical Ingredients (API) business together with Manufacturing facilities located at plot Nos.A-88 and D-10,MIDC, Kurkumbh, Pune , Maharashtra on a slump sale basis.
- 3 The current outstanding of principal value of Foreign Currency Convertible Bonds of USD 43,999,000 (Rs. 19949.85 Lacs) have become due for redemption on 9th November, 2010 and were not redeemed. These Bonds have accrued interest (yield to maturity) of USD 19.89 Mn. (Rs. 9017.33 Lacs). The Company is in constructive conversations with the Bond holders for the restructuring of the Bonds.However, the same has not yielded any results as yet . The Company has provided for these liabilities in its books of accounts along with exchange loss of Rs. 2363.45 Lacs. Further, due to the redemption default, there will be a default interest payable at 8% p.a. from the due date of redemption which has not yet been provided.
- 4 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 5 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 6 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

**7 Statement of Assets and Liabilities**

(Rs. in Lakhs)

Particulars	YEAR ENDED	YEAR ENDED
	31.03.2011	31.03.2010
	AUDITED	AUDITED
<b>SHAREHOLDERS FUND:</b>		
(a) Capital	5,028.07	5,028.06
(b) Reserve and Surplus	6,031.23	6,030.78
<b>LOAN FUNDS</b>	40,184.36	35,289.63
<b>FIXED ASSETS</b>	18,490.05	29,414.24
<b>INVESTMENTS</b>	6,761.64	7,761.64
<b>CURRENT ASSETS , LOANS AND ADVANCES</b>		
(A) Inventories	4,001.25	6,306.02
(B) Sundry Debtors	7,217.45	6,720.17
(c) Cash and Bank balance	2,623.78	3,251.27
(d) Other current assets		
(e) Loans and Advances	1,578.50	2,063.02
<b>Less: Current Liabilities and Provisions</b>		
(a) Liabilities and provision	3,207.37	3,532.65
Deferred Tax Assets/(Liability) (Net)	(1,496.14)	(1,150.00)
<b>MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)</b>	1.31	20.52
<b>PROFIT AND LOSS ACCOUNT</b>	(15,273.18)	6,505.74

For MARKSANS PHARMA LIMITED


  
MARK SALDANHA  
Managing Director.


Place: Mumbai.

Date: 28.05.2011

Visit us at [www.marksanspharma.com](http://www.marksanspharma.com)